Pulukuri Sai Murali Krishna, Estes Norman, Patel Jitendra, Rao Jasti S
Department of Cancer Biology and Pharmacology, College of Medicine, University of Illinois at Peoria, Peoria, IL 61656, USA.
Cancer Res. 2007 Feb 1;67(3):930-9. doi: 10.1158/0008-5472.CAN-06-2892.
Increased expression of urokinase plasminogen activator (uPA) has been reported in various malignancies including prostate cancer. However, the mechanism by which uPA is abnormally expressed in prostate cancer remains elusive. Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples. This aberrant expression is associated with cancer-linked demethylation of the uPA promoter. Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo. Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.
据报道,包括前列腺癌在内的多种恶性肿瘤中尿激酶型纤溶酶原激活剂(uPA)的表达均有所增加。然而,uPA在前列腺癌中异常表达的机制仍不清楚。在此,我们发现,uPA在高比例的人类前列腺癌组织中异常表达,但在肿瘤匹配的非肿瘤相邻组织或良性前列腺增生样本中很少表达。这种异常表达与uPA启动子的癌症相关去甲基化有关。此外,用去甲基化抑制剂S-腺苷甲硫氨酸处理或稳定表达uPA短发夹RNA可显著抑制uPA在体外的表达和肿瘤细胞侵袭,以及在体内的肿瘤生长和肺转移发生率。总体而言,这些发现强烈表明,DNA去甲基化是uPA异常表达的常见机制,也是人类前列腺肿瘤恶性进展的关键促成因素。